Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Eudragit, a Nifty Polymer for Anticancer Preparations: A Patent Review

Author(s): Priyanka Kriplani* and Kumar Guarve

Volume 17, Issue 1, 2022

Published on: 30 November, 2021

Page: [92 - 101] Pages: 10

DOI: 10.2174/1574892816666211013113841

Price: $65

Abstract

Background: Polymers are the backbone of modern pharmaceutical formulations and drug delivery technologies. Polymers that may be natural, synthetic, or semisynthetic are used to control the release of drugs in a pre-programmed fashion. The drug delivery systems are mainly prepared to enhance the bioavailability, site-specific release, sustained release, controlled release, i.e., to modify the release of drug from dosage form may be a tablet, capsule, etc.

Objectives: The objective of the present study is to overview the recent patents concerning the application of eudragit in the prevention of cancer and other ailments. Eudragit polymers are polymethacrylates and may be anionic, cationic, or non-ionic polymers of methacrylic acid, dimethylaminoethyl methacrylates, and methacrylic acid esters in varying ratios. Eudragit is available in various grades with solubilities at different pH, thus helping the formulators design the preparation to have a well-defined release pattern.

Methods: In this review, patent applications of eudragit in various drug delivery systems employed to cure mainly cancer are covered.

Results: Eudragit has proved its potential as a polymer to control the release of drugs as coating polymer and formation of the matrix in various delivery systems. It can increase the bioavailability of the drug by site-specific drug delivery and can reduce the side effects/toxicity associated with anticancer drugs.

Conclusion: The potential of eudragit to carry the drug may unclutter novel ways for therapeutic intercessions in various tumors.

Keywords: Brain, breast, cancer, colon, eudragit, lung, polymer, prostate.

« Previous Next »
[1]
Rowe RC, Sheskey PJ, Qinn ME. Handbook of Pharmaceutical Excipients. 6th ed. USA: Pharmaceutical Press 2009.
[2]
Theuer C. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors. US20170312233A1, 2017.
[3]
Babul N, Rehni AK. Oral pharmaceutical compositions of buprenorphine and another opioid receptor agonist. US20160176890A1, 2016.
[4]
Patra N, Priya R, Swain S, Jena GK, Panigrahi KC, Ghose D. Pharmaceutical significance of Eudragit. RE:view 2017; 3: 33.
[5]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[6]
National Institutes of Health; National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program Cancer stat facts: colorectal cancer. Available from: https://seer.cancer.gov/statfacts/html/colorect.html
[7]
Bailey CE, Hu CY, You YN, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg 2015; 150(1): 17-22.
[http://dx.doi.org/10.1001/jamasurg.2014.1756] [PMID: 25372703]
[8]
Riihimäki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep 2016; 6: 29765.
[http://dx.doi.org/10.1038/srep29765] [PMID: 27416752]
[9]
Andremont A, Huguet H. Colonic delivery using zn/pectin beads with a eudragit coating. EP2081557A1, 2009.
[10]
Katz D. Tablet with remedial composition and methods for treating medical disorders and ailments. US20090035371A1, 2012.
[11]
Thakral NK, Ray AR, Majumdar DK. Eudragit S-100 entrapped chitosan microspheres of valdecoxib for colon cancer. J Mater Sci Mater Med 2010; 21(9): 2691-9.
[http://dx.doi.org/10.1007/s10856-010-4109-2] [PMID: 20535630]
[12]
Sood A, Dev A, Mohanbhai SJ, et al. ACS Appl Nano Mater 2019; 2(10): 6409-17.
[http://dx.doi.org/10.1021/acsanm.9b01377]
[13]
Marcus S. Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms. US20200038345A1, 2020.
[14]
Allemandi DA, Boiero C, Garreta JMI, et al. Albumin nanoparticles for the treatment of cancer and ocular diseases. US20200138914A1, 2020.
[15]
Fratter A. Formulation for low bioavailability substances containing a n-acetylcysteine-chitosan salt. EP2849731B1, 2017.
[16]
Deol PK, Kaur IP. Improving the therapeutic efficiency of ginger extract for treatment of colon cancer using a suitably designed multiparticulate system. J Drug Target 2013; 21(9): 855-65.
[http://dx.doi.org/10.3109/1061186X.2013.829076] [PMID: 23962278]
[17]
Saraf A, Dubey N, Dubey N, Sharma M. Box behnken design based development of curcumin loaded eudragit s100 nanoparticles for site-specific delivery in colon cancer. Research J Pharm and Tech 2019; 12(8): 3672-8.
[http://dx.doi.org/10.5958/0974-360X.2019.00627.9]
[18]
S Kumar V, Rijo J, M S. Guargum and Eudragit® coated curcumin liquid solid tablets for colon specific drug delivery. Int J Biol Macromol 2018; 110: 318-27.
[http://dx.doi.org/10.1016/j.ijbiomac.2018.01.082] [PMID: 29378277]
[19]
Wu L, Qian C, Juan Y. Controlled-release medicine preparation for treatment of local advanced rectal cancer. CN104490839A, 2015.
[20]
Asfour MH, Mohsen AM. Formulation and evaluation of pH-sensitive rutin nanospheres against colon carcinoma using HCT-116 cell line. J Adv Res 2017; 9: 17-26.
[http://dx.doi.org/10.1016/j.jare.2017.10.003] [PMID: 30034879]
[21]
Baohua M, Lei Q, Laixiang Z. A kind of preparation method of controlled-release pharmaceutical formulation for Locally Advanced rectum cancer treatment. CN104666271B, 2018.
[22]
Pandey S, Vijayendra Swamy SM, Ubaid Ulla UM, Gupta A, Patel H, Yadav JS. Cell line and augument cellular uptake study of statistically optimized sustained release capecitabine loaded Eudragit S100/PLGA(poly(lacticco- glycolic acid)) nanoparticles for colon targeting. Curr Drug Deliv 2017; 14(6): 887-99.
[http://dx.doi.org/10.2174/1567201813666160817150621] [PMID: 27538461]
[23]
Agrawal D, Ranawat MS, Chauhan CS, Kamble R. Formulation and characterisation of colon targeted ph dependent microspheres of capecitabine for colorectal cancer. J Drug Deliv Ther 2013; 3(6): 215-22.
[24]
Bhatnagar P, Gupta KC. Oral administration of eudragit coated bromelain encapsulated plga nanoparticles for effective delivery of bromelain for chemotherapy in vivo. 2013 29th Southern Biomedical Engineering Conference. Miami, FL, USA. 2013; pp. 47-8.
[25]
Tao D, Jia C, Yuan L, Gang Y, Hong Y. Anti tumour drug oral colon targeting preparation and its preparing method. CN1977972A, 2007.
[26]
Aisha AFA, Abdulmajid AMS, Ismail Z, Alrokayan SA, Abu-Salah KA. Development of polymeric nanoparticles of garcinia mangostana xanthones in eudragit RL100/RS100 for anti-colon cancer drug delivery. J Nanomater 2015; 1-12.
[http://dx.doi.org/10.1155/2015/701979]
[27]
Subudhi MB, Jain A, Jain A, et al. Eudragit S100 coated citrus pectin nanoparticles for colon targeting of 5-fluorouracil. Materials (Basel) 2015; 8(3): 832-49.
[http://dx.doi.org/10.3390/ma8030832] [PMID: 28787974]
[28]
Bansal V. Pharmacokinetic and biodistribution analysis of 5-fluorouracil- and celecoxib-loaded eudragit s100-coated chitosan microspheres intended for colon-specific delivery. Asian J Pharm 2018; 12(4): 1-12.
[29]
Ramzy L, Metwally AA, Nasr M, Awad GAS. Novel thymoquinone lipidic core nanocapsules with anisamide-polymethacrylate shell for colon cancer cells overexpressing sigma receptors. Sci Rep 2020; 10(1): 10987.
[http://dx.doi.org/10.1038/s41598-020-67748-2] [PMID: 32620860]
[30]
Bin Z, Qiong W, Jingxiong L, et al. Anti-cancer pellet and colonic targeting agent. CN103191108A, 2014.
[31]
Xin L, Changxin Z. Controlled-release colon targeting drug administration preparation and preparation method thereof. CN101780055A, 2010.
[32]
Shaked Z, McGinity J. Pharmaceutical formulation containing DFMO for the treatment of cancer. US6277411B1, 2001.
[33]
Khan FA, Lammari N, Muhammad Siar AS, et al. Quantum dots encapsulated with curcumin inhibit the growth of colon cancer, breast cancer and bacterial cells. Nanomedicine (Lond) 2020; 15(10): 969-80.
[http://dx.doi.org/10.2217/nnm-2019-0429] [PMID: 32223518]
[34]
Carlos R, González B, Buser T, Goutte FJC. A delayed release drug formulation. WO2013164315A1, 2013.
[35]
Comiskey S, Shailubhai K. Formulations of guanylate cyclase C agonists and methods of use. AU2009322285B2, 2011.
[36]
Loury DJ, Buggy JJ, Mody TD, Verner EJ, Purro N, Balasubramanian S. Formulations of histone deacetylase inhibitor and uses thereof. US10105552B2, 2018.
[37]
Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol 2015; 151(10): 1081-6. [PubMed]. [Google Scholar].
[http://dx.doi.org/10.1001/jamadermatol.2015.1187] [PMID: 25928283]
[38]
Surveillance, epidemiology, and end results program, national cancer institute. SEER stat fact sheets: Melanoma of the skin. Available from: http://seer.cancer.gov/statfacts/html/melan.html
[39]
Linos E, Katz KA, Colditz GA. Skin Cancer-The Importance of Prevention. JAMA Intern Med 2016; 176(10): 1435-6.
[http://dx.doi.org/10.1001/jamainternmed.2016.5008] [PMID: 27459394]
[40]
Theuer C. Enhancement of anticancer activity by combination therapy with BER inhibitors. ES2602475T3, 2017.
[41]
Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370(8): 699-708.
[http://dx.doi.org/10.1056/NEJMoa1308573] [PMID: 24552317]
[42]
Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370(8): 709-22.
[http://dx.doi.org/10.1056/NEJMoa1308345] [PMID: 24552318]
[43]
Smith MA, Reaman GH. Remaining challenges in childhood cancer and newer targeted therapeutics. Pediatr Clin North Am 2015; 62(1): 301-12.
[http://dx.doi.org/10.1016/j.pcl.2014.09.018] [PMID: 25435124]
[44]
Brinkman TM, Krasin MJ, Liu W, et al. Long-term neurocognitive functioning and social attainment in adult survivors of pediatric CNS tumors: results from the St Jude Lifetime Cohort Study. J Clin Oncol 2016; 34(12): 1358-67.
[http://dx.doi.org/10.1200/JCO.2015.62.2589] [PMID: 26834063]
[45]
Chemaitilly W, Armstrong GT, Gajjar A, Hudson MM. Hypothalamic-pituitary axis dysfunction in survivors of childhood CNS tumors: importance of systematic follow-up and early endocrine consultation. J Clin Oncol 2016; 34(36): 4315-9.
[http://dx.doi.org/10.1200/JCO.2016.70.1847] [PMID: 27998231]
[46]
Phoenix TN, Patmore DM, Boop S, et al. Medulloblastoma genotype dictates blood brain barrier phenotype. Cancer Cell 2016; 29(4): 508-22.
[http://dx.doi.org/10.1016/j.ccell.2016.03.002] [PMID: 27050100]
[47]
Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 2007; 25(16): 2306-12.
[http://dx.doi.org/10.1200/JCO.2006.10.0677] [PMID: 17538177]
[48]
Mackay A, Burford A, Carvalho D, et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 2017; 32(4): 520-537.e5.
[http://dx.doi.org/10.1016/j.ccell.2017.08.017] [PMID: 28966033]
[49]
Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell 2017; 31(3): 326-41.
[http://dx.doi.org/10.1016/j.ccell.2017.02.009] [PMID: 28292436]
[50]
Gilbertson RJ. Mapping cancer origins. Cell 2011; 145(1): 25-9.
[http://dx.doi.org/10.1016/j.cell.2011.03.019] [PMID: 21458665]
[51]
Diederich A, Kunzler H, Graner O. Pharmaceutical compositions comprising everolimus. TW201503912A, 2015.
[52]
Lane H, Oâ´Reilly T, Wood JM. 40-O- (2-hydroxyethyl) rapamycin for use as the sole active ingredient in the treatment of solid brain tumors other than lymphatic cancer. SK288524B6, 2018.
[53]
Sànchez PC. Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis. US20170231932A1, 2017.
[54]
Lee PA, Winski SL, Koch K. Treatment of brain cancer. US20150110780A1, 2015.
[55]
Cuzick J, Thorat MA, Andriole G, et al. Prevention and early detection of prostate cancer. Lancet Oncol 2014; 15(11): e484-92.
[http://dx.doi.org/10.1016/S1470-2045(14)70211-6] [PMID: 25281467]
[56]
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2008; 127(12): 2893-917.
[57]
Kiciński M, Vangronsveld J, Nawrot TS. An epidemiological reappraisal of the familial aggregation of prostate cancer: A meta-analysis. PLoS One 2011; 6(10): e27130.
[http://dx.doi.org/10.1371/journal.pone.0027130] [PMID: 22073129]
[58]
Merrill RM, Sloan A. Risk-adjusted incidence rates for prostate cancer in the United States. Prostate 2012; 72(2): 181-5.
[http://dx.doi.org/10.1002/pros.21419] [PMID: 21538427]
[59]
Goggins WB, Wong G. Cancer among Asian Indians/Pakistanis living in the United States: low incidence and generally above average survival. Cancer Causes Control 2009; 20(5): 635-43.
[http://dx.doi.org/10.1007/s10552-008-9275-x] [PMID: 19067192]
[60]
Verreck G. Anticancer compositions. WO2016090105A1, 2016.
[61]
Lomuscio S, Ma H, Matchett MA, Sandhu HK, Shah NH, Zhang Y. Pharmaceutical composition with improved bioavailability. US20170000764A1, 2018.
[62]
Sànchez PC, Gallego GG, Gorman ISDT, et al. Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer. US10278940B2, 2019.
[63]
Yaffe MB, Patterson JC. Combination therapies and methods of use thereof for treating cancer. US9566280B2, 2017.
[64]
Carson DA, Leoni LM, Cottam HB. Indole compounds useful for the treatment of cancer. US7151100B1, 2006.
[65]
Banerjee PP, Jagadeesh S, Paige M, Ditmer K, Brown ML. Carbazole derivatives useful as medicaments in cancer therapy. WO2008051523A2, 2008.
[66]
Cancer-Its various types along with causes, symptoms, treatments and stages Cancer info guide 2009. Available from: http://www.cancer-info-guide.com/
[67]
Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: An overview. J Adv Pharm Technol Res 2010; 1(2): 109-26.
[PMID: 22247839]
[68]
Burke M, White M, Watts MC, et al. Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders. US20020076442A1, 2002.
[69]
Kiyono K, Onishi K, Nagahama Y, Watanabe T. Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer. WO2014189152A1, 2014.
[70]
Bin W. Indirubin solid dispersion composition. WO2015095659A2, 2015.
[71]
Weng CF, Chia YC, Lee CH, Varadharajan T. HCD formulation for cancer treatment. US9682063B2, 2017.
[72]
World Health Organisation. Cancer 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer (accessed 13-10, 2020).
[73]
Schabath MB, Cote ML, Biomarkers P. Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev 2019; 28(10): 1563-79.
[http://dx.doi.org/10.1158/1055-9965.EPI-19-0221] [PMID: 31575553]
[74]
Huang KL, Wang SY, Lu WC, Chang YH, Su J, Lu YT. Effects of low-dose computed tomography on lung cancer screening: A systematic review, meta-analysis, and trial sequential analysis. BMC Pulm Med 2019; 19(1): 126.
[http://dx.doi.org/10.1186/s12890-019-0883-x] [PMID: 31296196]
[75]
Brodersen J, Thorsen H, Kreiner S. Consequences of screening in lung cancer: development and dimensionality of a questionnaire. Value Health 2010; 13(5): 601-12.
[http://dx.doi.org/10.1111/j.1524-4733.2010.00697.x] [PMID: 20345552]
[76]
van den Bergh KA, Essink-Bot M-L, Borsboom GJ, Scholten ET, van Klaveren RJ, de Koning HJERJ. Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial. Eur Respir J 2011; 38(1): 154-61.
[http://dx.doi.org/10.1183/09031936.00123410] [PMID: 21148229]
[77]
Byrne MM, Weissfeld J, Roberts MS. Anxiety, fear of cancer, and perceived risk of cancer following lung cancer screening. Med Decis Making 2008; 28(6): 917-25.
[http://dx.doi.org/10.1177/0272989X08322013] [PMID: 18725404]
[78]
Fry DS, Lindemann CM, Preigh M, et al. Solid dispersions of a erb2 (her2) inhibitor. US20170136022A1, 2017.
[79]
Yurtdaş-Kırımlıoğlu G, Görgülü Ş, Berkman MS. Novel approaches to cancer therapy with ibuprofen-loaded Eudragit® RS 100 and/or octadecylamine-modified PLGA nanoparticles by assessment of their effects on apoptosis. Drug Dev Ind Pharm 2020; 46(7): 1133-49.
[http://dx.doi.org/10.1080/03639045.2020.1776319] [PMID: 32476502]
[80]
Riveiro ME, Raymond E, Bertoni F. Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds. CA2951211A1, 2015.
[81]
Willibrord P, Thies P. Pharmaceutical preparation with an anti-tumour activity. EP0129822A2, 1985.
[82]
Zhang B, Guo R, Hu Y, et al. Design, synthesis and biological evaluation of valepotriate derivatives as novel antitumor agents. RSC Advances 2017; 7: 31899-906.
[http://dx.doi.org/10.1039/C6RA27478A]
[83]
Liversidge G, Jenkins S. Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer. US20070122481A1, 2007.
[84]
Quart B. Compositions and methods for treating or preventing colon cancer. EP2529626B1, 2012.
[85]
Sheikh SN, Ukawala M, Gandhi T, Srivastava BK, Kannan ME, Desai RC. Olaparib co-precipitate and preparation method thereof. US20170105937A1, 2017.
[86]
Backstrom JT, Etter JB, Lai M. Oral formulations of cytidine analogs and methods of use thereof. AU2013202665B2, 2015.
[87]
Yanai YK. Controlled release composition. JP4837895B2, 2011.
[88]
Anothra P, Pradhan D, Naik PK, Ghosh G, Rath G. Development and characterization of 5-fluorouracil nanofibrous film for the treatment of stomach cancer. J Drug Deliv Sci Technol 2021; 61: 102219.
[http://dx.doi.org/10.1016/j.jddst.2020.102219]
[89]
Debregeas P, LeDuc G, Oury P, Suplie P. Microgranules containing cisplatin. US6458389B1, 2002.
[90]
Rudnic EM, Isbister JD, Treacy DJ, Wassink SE. Multiple-delayed release anti-neoplastic product, use and formulation thereof. US7105174B2, 2006.
[91]
Lee SB. Pharmaceutical composition comprising arsenite for the treatment of malignancy. US20120045520A1, 2012.
[92]
Sharp ZD, Strong JR, Galvan V, Oddo S, Wheeler H. Rapamycin microcapsules and their use for cancer treatment. ES2645692T3, 2017.
[93]
Kanthamneni N, Yung B, Lee RJ. Effect of Eudragit on In Vitro Transfection Efficiency of PEI-DNA Complexes. Anticancer Res 2016; 36(1): 81-5.
[PMID: 26722030]
[94]
Friedman M, Czernimski R, Gutkind S, Steinberg D, Gati I, Nudelman Z. Sustained release delivery systems for the prevention and treatment of head and neck cancers. WO2011024168A2, 2011.
[95]
Bhilegaonkar S, Parvatkar A. Eudragit: A versatile and robust platform. Int J Pharm Sci Res 2020; 11(6): 2626-35.
[96]
Nikam VK, Kotade KB, Gaware VM, et al. Eudragit a versatile polymer: A review. Pharmacologyonline 2011; 1: 152-64.
[97]
Prusty A, Gupta BK. Role of chitosan and eudragit in polymer based extended-release matrix tablets-A review. Int J Pharm Sci Res 2017; 8: 4973-82.

Rights & Permissions Print Cite
Article Metrics
45
1
© 2024 Bentham Science Publishers | Privacy Policy